22 results about "Neurological Damage" patented technology

A polypeptide derivative or a pharmaceutically acceptable salt thereof, through the introduction of fatty acid side chains at specific sites of the ISP polypeptide, and / or the formation of a cyclic structure within the polypeptide by generating amide bonds between E and K, significantly improves the stability and activity of the resulting polypeptide derivative. This allows for better preparation of drugs for treating diseases related to nerve damage.

This invention provides the application of *Bifidobacterium animalis* subsp. lactis CP-9 in the preparation of compositions that promote neurodevelopment and alleviate cognitive impairment and nerve damage. This invention discovers that *Bifidobacterium animalis* subsp. lactis CP-9 can improve abnormal neurodevelopment, cognitive impairment, and nerve damage, and has a protective effect on the nervous system and overall health. This novel application expands the application scope of *Bifidobacterium animalis* subsp. lactis as a probiotic, and is of great significance for further exploring the functions of probiotics and developing probiotics with higher nutritional and health benefits. It also opens up new avenues and solutions for protecting nervous system health and preventing nervous system diseases through dietary strategies.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

This invention relates to the field of traditional Chinese medicine preparation technology, and particularly to a traditional Chinese medicine composition for treating cancer pain and numbness, as well as its preparation and application. This invention designs a traditional Chinese medicine composition for cancer pain and numbness, comprising: *Houttuynia cordata*, *Aconitum carmichaelii*, processed *Aconitum carmichaelii*, centipede, *Astragalus membranaceus*, *Ephedra sinica*, clove, frankincense, ephedra, menthol, and azone. The scientifically formulated combination of principal, assistant, and adjuvant herbs allows for multi-target action on both "cancer pain" (inflammation, compression, nerve infiltration) and "CIPN" (nerve damage), resulting in a superior analgesic effect, while also possessing anti-inflammatory, anti-swelling, potential tumor-suppressing, and nerve-repairing effects. The traditional Chinese medicine composition is prepared into a traditional Chinese medicine ointment, which is administered transdermally, allowing a high concentration of the drug to act directly on the lesion, avoiding the systemic side effects (addiction, constipation, etc.) associated with oral opioids. This is especially suitable for patients who cannot take oral opioids or cannot tolerate them.

The present application relates to a kind of pentosus PP90 for preventing and treating alcoholic nerve injury and its application, wherein pentosus PP90 is preserved in China Microbial Culture Collection Center, and the preservation number is CGMCC NO.32034.The fermentation product of the pentosus PP90 can degrade the alcoholicity of alcohol, can produce ethanol dehydrogenase and acetaldehyde dehydrogenase, can improve the viability of nerve cell, can regulate the expression of cytokine, can inhibit the activation of astrocyte, can regulate the expression of brain-derived neurotrophic factor, can improve the level of disturbed neurotransmitter, and can be used for preparing product for preventing and treating alcoholic nerve injury or improving alcoholic nerve injury.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

This invention provides a composite composition containing nervonic acid and its use in brain nerve repair, belonging to the field of biotechnology. The invention uses nervonic acid and phosphatidylserine, combined with plant extracts fermented by a microbial concoction of *Lactobacillus acidophilus*: *Lactobacillus rhamnosus*: *Bacillus belyssae* = (2-3):1:1, to form a composite composition. This scientific formulation achieves synergistic effects from multiple components, improving neurological deficits, reducing cerebral infarction volume, decreasing the release of neurotrophic markers, and upregulating neurotrophic factor expression through multi-target synergistic effects. Furthermore, this synergistic effect depends on specific component ratios, providing crucial experimental support for the development of subsequent brain-protective functional compositions. This composition can be widely applied to the preparation of brain nerve repair drugs, functional foods, and dietary supplements, possessing promising industrialization prospects and clinical value.

A system to rehabilitate stroke or traumatic brain injury survivors includes a brain machine interface that receives brain signals from the brain of a patient. The brain signals represent motor intent of the patient with respect to a hand of the patient that has impaired dexterous hand function due to neurological injury. A limb interface mounts to the hand of the patient. The limb interface detects feedback in the hand that results from the brain signals and helps to control the hand in accordance with the motor intent of the brain signals. The system also includes a processor operatively coupled to the brain machine interface and the limb interface. The processor is configured to synchronize the motor intent with the feedback to increase plasticity between sensory and motor areas of the brain to improve voluntary control of the hand, including dexterous hand functions such as multiple types of grasp.

Embodiments of the disclosure include treatments of subconcussive and / or concussive brain damage by administering fibroblasts and / or fibroblasts cultured with one or more types of immunocytes. In one specific embodiment fibroblasts are cultured with monocytes in the presence of patient-specific T cells, and subsequently the T cells are re-administered into the patient. In one particular embodiment, products derived from fibroblast-immunocyte mixtures are comprised of cellular lysate, apoptotic bodies, exosomes, and / or other microvesicles. In one embodiment, the fibroblast cells and / or products derived from the fibroblast cells are administered subsequent to one or multiple head injuries. In other embodiments, products are administered in combination with neurorestorative and / or neuroprotective interventions.

This application discloses the application of Bcl11a in the preparation of drugs for nerve injury repair, belonging to the field of biomedical technology. The nerve injury is a central nervous system injury. Overexpression of Bcl11a promotes the transdifferentiation of an intermediate state astrocyte in the cerebral cortex into pyramidal neurons. Using Bcl11a as a molecular intervention target, targeting the M1 motor area of ​​the cerebral cortex, overexpression of Bcl11a in astrocyte subset 2 promotes the reprogramming of astrocytes into pyramidal neurons, promoting the repair of central nervous system injury. Using spatial transcriptome sequencing technology and single-cell sequencing technology, the dynamic trajectory between astrocytes and pyramidal cells was depicted, supporting the transformation of an intermediate transitional state astrocyte in the cortex into pyramidal cell subset 3 after spinal cord injury, indicating that Bcl11a and Zmart4 are key transcription factors in the connection between pyramidal cells and glial cells.

This invention belongs to the field of nerve damage repair drugs, specifically involving the application of nano-metal sulfides in the preparation of drugs for treating diseases caused by brain nerve damage. Its advantages are: it provides a new approach to preparing nerve damage repair drugs; the materials are readily available, low in cost, and easy to prepare.

The application discloses a compound with neuroprotective activity, a preparation method and application. A new compound of diketopiperazine alkaloids is separated from a fermentation product of Aspergillus, the compound is stable in performance, has no cytotoxicity, and has significant neuroprotective activity. The compound can improve the cell survival rate of a nerve injury in vitro model at a lower concentration, inhibit the generation of active oxygen and malondialdehyde, and obviously increase the expression amount of superoxide dismutase, and has the effects of antioxidation and anti-nerve injury, and has a wide application prospect in the preparation of medicines for preventing and treating neurodegenerative diseases.

This invention belongs to the field of biomedical technology and specifically relates to the use of divalent metal lactates in the manufacture of products for the prevention, improvement, repair, and treatment of nerve damage. Preferably, the divalent metal lactate includes one or more of the following: calcium lactate, magnesium lactate, zinc lactate, and ferrous lactate. This invention provides a novel treatment method for repairing damage to the central and peripheral nervous systems and has broad potential applications in the treatment and repair of central nervous system damage caused by trauma or other causes, or peripheral neuritis or peripheral nerve sensory abnormalities caused by viruses, diabetes, chemotherapy drugs, etc.

This invention discloses a class of 3-substituted phthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of drugs for the treatment and / or prevention of neurological diseases, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

This invention belongs to the field of biomedicine and provides the application of LAPF and its agonists in the preparation of drugs for the treatment or prevention of postherpetic neuralgia. This invention targets spinal microglia by administering LAPF protein, a gene vector encoding LAPF, or an upregulator of their expression / activity, restoring their antiviral immune function, inhibiting neuroinflammation, and promoting the expression of neuroprotective factors. Animal experimental results show that administering LAPF protein, a gene vector encoding LAPF, or an upregulator of their expression / activity can significantly reduce mechanical hyperalgesia, decrease HSV-1 / VZV-related nerve damage, and effectively alleviate symptoms of chronic neuralgia.

The present application relates to the technical field of intelligent medical prediction, in particular to a kind of intelligent early warning method and system for adverse reactions of tumor patient chemotherapy drug, method includes: the gene sequencing data of current patient, time sequence physiological index data are input to network model, network model output damage stage;The training data set of network model includes: gene sequencing data, time sequence physiological index data and damage stage;The acquisition process of damage stage includes: based on gene sequencing data, the relative metabolic rate thereof to chemotherapy drug is acquired, and then the relative speed of its in-vivo toxicity accumulation is determined;After the time sequence physiological index data of meaningless physiological fluctuation of historical patient is smoothed, the nerve damage change curve is acquired according to time sequence physiological index data, and then whether there is potential subclinical signal segment in it is identified, if yes, then it is judged damage stage according to this.The present application can realize individualized, accurate risk prediction before irreversible nerve damage occurs caused by chemotherapy.

This invention discloses an anti-human MBP monoclonal antibody and its applications. The complementarity-determining region (CDR) of the heavy chain variable region of the monoclonal antibody has the amino acid sequences shown in SEQ ID NO. 1-3, and the CDR of the light chain variable region has the amino acid sequences shown in SEQ ID NO. 4-6. This invention uses a chemically synthesized polypeptide as an immunogen to immunize mice. Through cell fusion, screening, and subcloning, a monoclonal cell line that efficiently secretes anti-human MBP monoclonal antibodies is obtained. The antibody obtained by this invention has high specificity and high binding capacity, effectively targeting and binding MBP protein from serum. It is suitable for detecting MBP protein in blood, thereby evaluating neurological injury diseases that may cause changes in MBP protein concentration, and providing more convenient conditions for the diagnosis of mild traumatic brain injury.

This invention discloses a class of piperidine alkyl dihydroxyphthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of medicaments for treating and / or preventing diseases by means of anti-oxidative stress, inhibition of amyloid aggregation, metal ion complexation, or anti-neuroinflammatory effects, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

The application discloses a strain capable of promoting vitamin B 12 absorption and improving cognitive function, and application thereof, and belongs to the technical field of biotechnology. The application provides a Paraglactobacillus paracus CCFA1525, which is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 67380 and a preservation date of November 18, 2025. The Paraglactobacillus paracus CCFA1525 can up-regulate the expression of key proteins in the ileum, promote the absorption of vitamin B 12 , relieve nerve damage and cognitive impairment caused by sleep deprivation, and thus plays a significant neuroprotective role. Therefore, the Paraglactobacillus paracus CCFA1525 can be used for developing products with anti-nerve damage function, and is suitable for improving cognitive impairment caused by vitamin B 12 absorption disorder, and has good functional application prospect and industrial production potential. 12 ​

This invention discloses a genetically engineered product based on the Elavl4 / miR-301a-5p / Nurr1 axis and its applications, belonging to the fields of genetic engineering and neuroprotection. Addressing the technical shortcomings of unclear molecular mechanisms, limited intervention methods, and lack of standardized detection tools for atrazine (ATR)-induced dopaminergic neuronal damage, this invention provides the first experimental verification that Elavl4–miR-301a-5p–Nurr1 is a key ceRNA regulatory axis in ATR neurotoxicity. The regulatory mechanism is clarified as follows: ATR exposure downregulates Elavl4, releasing its sponge-like adhesion to miR-301a-5p, thereby inhibiting Nurr1 expression and leading to neuronal damage. This invention provides a genetically engineered product targeting this regulatory axis, which can significantly reverse ATR-induced decreased cell viability, increased apoptosis, and PD-like behavioral defects in animals; it also provides a biomarker composition containing Elavl4, miR-301a-5p, and Nurr1 for assessing ATR exposure risk and the degree of neuronal damage. This invention has an innovative mechanism and strong targeting, and can be applied to the development of neuroprotective drugs, the construction of high-throughput screening models and toxicity assessment, showing great potential for translation.

This invention discloses a virtual-real fusion method and apparatus based on multi-scale registration, relating to the fields of computer vision and 3D object pose estimation. It enables precise registration of real-time endoscopic images with CBCT 3D models, providing anatomical visualization navigation for impacted wisdom tooth extraction and reducing the risk of nerve damage. This method requires no feature point detection and matching, has low texture requirements, and is suitable for scenarios where endoscopic images lack rich texture. Multi-scale optimization strategies and adaptive regularization mechanisms improve optimization efficiency and stability, while trajectory consistency detection and correction mechanisms enhance the system's robustness.

A system and methods are disclosed for enabling or improving control of cardiovascular and / or vasomotor autonomic functions in a patient having a neurologically derived paralysis or a nervous system disorder.